The management of advanced genitourinary malignancies has undergone a major transformation with the advent of novel drugs and targeted therapies in recent years. Assessment of the treatment risks and benefits is required for each patient and therefore better knowledge of the different clinical and molecular aspects of these diseases is warranted. The results of further studies and biomarker validations are expected to provide more treatment options and improve outcomes in the future management of genitourinary malignancies.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356: 125–134, 2007.
2.
MotzerR.J., HutsonT.E., TomczakP., MichaelsonD., BukowskiR.M., RixeO., OudardS., NegrierS., SzczylikC., KimS.T., ChenI., BycottP.W., BaumC.M., FiglinR.A.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356: 115–124, 2007.
3.
SternbergC.N., DavisI.D., MardiakJ., SzczylikC., LeeE., WagstaffJ., BarriosC.H., SalmanP., GladkovO.A., KavinaA., ZarbáJ.J., ChenM., McCannL., PanditeL., RoychowdhuryD.F., HawkinsR.E.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28: 1061–1068, 2010.
4.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370: 2103–2111, 2007.
5.
RiniB.I., HalabiS., RosenbergJ.E., StadlerW.M., VaenaD.A., ArcherL., AtkinsJ.N., PicusJ., CzaykowskiP., DutcherJ., SmallE.J.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol, 28: 2137–2143, 2010.
6.
HudesG., CarducciM., TomczakP., DutcherJ., FiglinR., KapoorA., StaroslawskaE., SosmanJ., McDermottD., BodrogiI., KovacevicZ., LesovoyV., Schmidt-WolfI.G., BarbarashO., GokmenE., O'TooleT., LustgartenS., MooreL., MotzerR.J.; Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med, 356: 2271–2281, 2007.
7.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo controlled phase III trial. Lancet, 372: 449–456, 2008.
HutsonT.E.: Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist, 16: 14–22, 2011.
10.
PortaC., SzczylikC., EscudierB.: Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. Crit Rev Oncol Hematol, July 4, 2011 [Epub ahead of print].
11.
HutsonT.E., BukowskiR.M., CoweyC.L., FiglinR., EscudierB., SternbergC.N.: Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol, 77: 48–62, 2011.
NozawaM., MatsumuraN., YasudaM., OkudaY., UemuraH.: Activity of retreatment with sorafenib for metastatic renal cell carcinoma. In: ASCO Genitourinary Cancers Symposium, February 17–19, Orlando, Florida, Abstract 404, 2011.
14.
HengD.Y., MackenzieM.J., VaishampayanU.N., BjarnasonG.A., KnoxJ.J., TanM.H., WoodL., WangY., KollmannsbergerC., NorthS., DonskovF., RiniB.I., ChoueiriT.K.: Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol, Nov 5, 2011 [Epub ahead of print].
15.
SadeghiS., AlbigesL., WoodL.S., BlackS.L., GilliganT.D., DreicerR., GarciaJ.A., EscudierB.J., RiniB.I.: Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer, Dec 2, 2011 [Epub ahead of print].
16.
MekhailT.M., Abou-JawdeR.M., BoumerhiG., MalhiS., WoodL., ElsonP., BukowskiR.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol, 23: 832–841, 2005.
17.
HengD.Y., XieW., ReganM., WarrenM.A., ChengT., NorthS.A., KnoxJ.J., KollmannsbergerC., McdermottD.F., GolshayanA.R., RiniB.I., ChoueiriT.K.: Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. In: ASCO Genitourinary Cancers Symposium, February 26–28, Orlando, Florida, Abstract 284, 2009.
18.
FurgeK.A., MacKeiganJ.P., TehB.T.: Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol, 11: 571–578, 2010.
19.
SchmidingerM., ZielinskiC.C., VoglU.M., BojicA., BojicM., SchukroC., RuhsamM., HejnaM., SchmidingerH.: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 26: 5204–5212, 2008.
20.
Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce: The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol, 69: 64–72, 2009.
21.
PortaC., ProcopioG., CartenìG., SabbatiniR.: Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int, 108: 250–257, 2011.
22.
BellmuntJ., ThéodoreC., DemkovT., KomyakovB., SengelovL., DaugaardG., CatyA., CarlesJ., Jagiello-GruszfeldA., KaryakinO., DelgadoF.M., HurteloupP., WinquistE., MorsliN., SalhiY., CulineS., von der MaaseH.: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol, 27: 4454–4461, 2009. Erratum: Winquist, Eric [added] In: J Clin Oncol, 28: 182, 2010.
